Search - tctmd.com

Displaying 141 - 160 of 971

Sort: Relevancy | Date

Presentation EuroPCR 2024

One-month DAPT followed by 5-month Ti - cagrelor monotherapy in acute coronary syndromes with DCB - results from REC-CAGEFREE II

Presenter: Ling Tao

May 15, 2024

Presentation EuroPCR 2024

Is coronary artery bypass surgery cost-effective compared with contemporary PCI? A FAME 3 analysis

Presenter: Frederik Zimmermann

May 15, 2024

News Conference News EuroPCR 2024

Stepwise DAPT De-escalation Shows Promise in DCB-Only PCI for ACS

Yael L. Maxwell

May 15, 2024

News Conference News EuroPCR 2024

ORBITA-2: Angina Phenotype Strongly Predicts PCI Response

Caitlin E. Cox

May 15, 2024

Presentation EuroPCR 2024

Methodological Insight: REC-CAGEFREE II Trial

Presenter: Robert Byrne

May 14, 2024

News Conference News SCAI 2024

Radial PCI Benefits Seen in Real-world Analysis, Mirroring RCTs

L.A. McKeown

May 10, 2024

News Daily News

Certain Periprocedural MIs Don’t Matter, New Data Allege

Michael O'Riordan

May 09, 2024

News Conference News SCAI 2024

PCI and TAVI Safe, Even When Done at the Same Time: TVT Registry

L.A. McKeown

May 07, 2024

News Daily News

TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction

Michael O'Riordan

May 06, 2024

News Conference News SCAI 2024

AI Picks Up on Info Operators Miss on Angiograms: AI-ENCODE

L.A. McKeown

May 03, 2024

News Daily News

Again and Again, Trials Back Short DAPT Post-PCI in ACS: Practice Slow to Shift

Yael L. Maxwell

May 03, 2024

News Conference News SCAI 2024

CALORI: More Support for Eschewing Fasting Protocols Preprocedure

L.A. McKeown

May 02, 2024

News Opinion CV Team Dispatch

May 2024 Dispatch for the CV Team

L.A. McKeown

May 01, 2024

News Daily News

FDA Approves Bioresorbable Scaffold for BTK Lesions

Michael O'Riordan

April 29, 2024

News Conference News ACC 2024

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

L.A. McKeown

April 08, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

$Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)$

Presentation ACC 2024

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Presenter: Rasha K. Al-Lamee

April 08, 2024

Presentation ACC 2024

PREVENT: Preventive PCI versus Medical Therapy Alone for Treatment of Vulnerable Atherosclerotic Coronary Plaques

Presenter: Seung-Jung Park

April 07, 2024

News Conference News ACC 2024

Long-Awaited RCT Data Show Survival Benefit With Impella CP: DanGer Shock

Caitlin E. Cox

April 07, 2024

News Conference News ACC 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

Shelley Wood

April 06, 2024

Advertisement

One-month DAPT followed by 5-month Ti - cagrelor monotherapy in acute coronary syndromes with DCB - results from REC-CAGEFREE II

Is coronary artery bypass surgery cost-effective compared with contemporary PCI? A FAME 3 analysis

Stepwise DAPT De-escalation Shows Promise in DCB-Only PCI for ACS

ORBITA-2: Angina Phenotype Strongly Predicts PCI Response

Methodological Insight: REC-CAGEFREE II Trial

Radial PCI Benefits Seen in Real-world Analysis, Mirroring RCTs

Certain Periprocedural MIs Don’t Matter, New Data Allege

PCI and TAVI Safe, Even When Done at the Same Time: TVT Registry

TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction

AI Picks Up on Info Operators Miss on Angiograms: AI-ENCODE

Again and Again, Trials Back Short DAPT Post-PCI in ACS: Practice Slow to Shift

CALORI: More Support for Eschewing Fasting Protocols Preprocedure

May 2024 Dispatch for the CV Team

FDA Approves Bioresorbable Scaffold for BTK Lesions

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

PREVENT: Preventive PCI versus Medical Therapy Alone for Treatment of Vulnerable Atherosclerotic Coronary Plaques

Long-Awaited RCT Data Show Survival Benefit With Impella CP: DanGer Shock

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content